Patent US4075340A successfully refreshed from Google Patents.
US4075340A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Thieno [2,3-C] pyridine derivatives and therapeutic composition containing same
Assignee: Parcor SARL
•
Filing: 1976-06-02
•
Granted: 1978-02-21
•
Expires: 1996-06-02
Abstract
Abstract This invention relates to derivatives having the formula: ##STR1## in which R 1 is hydrogen or alkyl having 1-6 carbon atoms; X is (CHR 2 ) m in which m is an integer from 2 to 15, or (CHR 2 ) n R 3 in which n is an integer from 1 to 15, R 2 is hydrogen, or a hydroxy, acyloxy or alkyl group having 1-6 carbon atoms, and the various symbols R 2 may have different meanings in each radical (CHR 2 ) when several radicals (CHR 2 ) are present, R 3 is a trichloromethyl, acetyl, carboxy or alkoxycarbonyl group, or a phenyl, phenoxy, benzoyl, thienyl or pyridyl radical optionally substituted with at least a halogen atom, or a hydroxy, nitro, amino, cyano, carboxy, alkyloxycarbonyl, alkyl having 1-6 carbon atoms, alkoxy having 1-6 carbon atoms or methylenedioxy group, and to the acid addition salts of the derivatives of the formula (I). Said derivatives have useful anti-inflammatory and anti-arrhythmic activities and an inhibiting action on blood platelet aggregation.
Inventors
- 👤 Jean-Pierre Maffrand
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 21:41
CPC Classifications
C; C07; C07D; C07D495/00; C07D495/02; C07D495/04; A; A61; A61P; A61P29/00; A61P7/00; A61P7/02; A61P9/00; A61P9/06
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
94 words
A compound having the following structure: ##STR6## in which R 1 is a member selected from the group consisting of hydrogen and methyl, with a proviso that when R 1 is hydrogen, X is a member selected from the group consisting of n-dodecyl, o-methoxycarbonylbenzyl o-carboxybenzyl 2-(5-chloro-thienyl)-methyl 2-acetoxy-2-p-chlorophenyl-ethyl 2-hydroxy-propyl 2-acetoxy-2-m.methoxyphenyl-ethyl o-nitrobenzyl p-nitrobenzyl o-cyanobenzyl 2-chloro-benzyl 3,4,5-trimethoxy-benzyl β-phenethyl m.methoxybenzyl p.chlorobenzyl m.chlorobenzyl 2-hydroxy-2-phenyl-ethyl p.methylbenzyl 3,4-dimethoxy-benzyl o.fluorobenzyl 2-hydroxy-2- p.chlorophenyl-ethyl 2,3,4-trimethoxy-benzyl 2-hydroxy-2-p.fluorophenyl-ethyl 2-hydroxy-2-p.methoxyphenyl-ethyl 2-hydroxy-3-p.methoxyphenoxy-propyl 3-oxo-butyl 2-hydroxy-3,3,3-trichloro-propyl 3,4-dimethoxy-benzyl and when R 1 is methyl, X is a member selected from the group consisting of 3,4,5-trimethoxy-benzyl 2-hydroxy-2-phenyl-ethyl 2-p.chlorophenyl-2-hydroxy-ethyl o-chlorobenzyl 2-hydroxy-2-p.methoxyphenyl-ethyl 2-hydroxy-2-m.methoxyphenyl-ethyl 2-(2,4-dimethoxy-phenyl)-2-hydroxyethyl.
Claim 2
Dependent Claim
94 words
A compound having the following structure: ##STR6## in which R 1 is a member selected from the group consisting of hydrogen and methyl, with a proviso that when R 1 is hydrogen, X is a member selected from the group consisting of n-dodecyl, o-methoxycarbonylbenzyl o-carboxybenzyl 2-(5-chloro-thienyl)-methyl 2-acetoxy-2-p-chlorophenyl-ethyl 2-hydroxy-propyl 2-acetoxy-2-m.methoxyphenyl-ethyl o-nitrobenzyl p-nitrobenzyl o-cyanobenzyl 2-chloro-benzyl 3,4,5-trimethoxy-benzyl β-phenethyl m.methoxybenzyl p.chlorobenzyl m.chlorobenzyl 2-hydroxy-2-phenyl-ethyl p.methylbenzyl 3,4-dimethoxy-benzyl o.fluorobenzyl 2-hydroxy-2- p.chlorophenyl-ethyl 2,3,4-trimethoxy-benzyl 2-hydroxy-2-p.fluorophenyl-ethyl 2-hydroxy-2-p.methoxyphenyl-ethyl 2-hydroxy-3-p.methoxyphenoxy-propyl 3-oxo-butyl 2-hydroxy-3,3,3-trichloro-propyl 3,4-dimethoxy-benzyl and when R 1 is methyl, X is a member selected from the group consisting of 3,4,5-trimethoxy-benzyl 2-hydroxy-2-phenyl-ethyl 2-p.chlorophenyl-2-hydroxy-ethyl o-chlorobenzyl 2-hydroxy-2-p.methoxyphenyl-ethyl 2-hydroxy-2-m.methoxyphenyl-ethyl 2-(2,4-dimethoxy-phenyl)-2-hydroxyethyl.
Claim 3
Dependent Claim
77 words
A compound having the following structure: ##STR7## in which R 1 is a member selected from the group consisting of hydrogen and methyl, with a proviso that when R 1 is hydrogen, X is a member selected from the group consisting of dodecyl phenacyl p-chlorophenacyl p-fluorophenacyl p-methoxyphenacyl 2-picolyl-N-oxide ethoxycarbonylmethyl acetonyl 2-carboxy-ethyl carboxymethyl and when R 1 is methyl, X is a member selected from the group consisting of phenacyl p-methoxyphenacyl o-methoxyphenacyl 2,4-dichloro-phenacyl p-chlorophenacyl p-fluorophenacyl 2,5-dimethoxy m-methoxyphenacyl 3.
Claim 4
Dependent Claim
77 words
A compound having the following structure: ##STR7## in which R 1 is a member selected from the group consisting of hydrogen and methyl, with a proviso that when R 1 is hydrogen, X is a member selected from the group consisting of dodecyl phenacyl p-chlorophenacyl p-fluorophenacyl p-methoxyphenacyl 2-picolyl-N-oxide ethoxycarbonylmethyl acetonyl 2-carboxy-ethyl carboxymethyl and when R 1 is methyl, X is a member selected from the group consisting of phenacyl p-methoxyphenacyl o-methoxyphenacyl 2,4-dichloro-phenacyl p-chlorophenacyl p-fluorophenacyl 2,5-dimethoxy m-methoxyphenacyl 3.
Claim 5
Dependent Claim
2 words
4-dihydroxy-phenacyl p-methylphenacyl
Claim 6
Dependent Claim
2 words
4-dihydroxy-phenacyl p-methylphenacyl
Claim 7
Dependent Claim
36 words
p-hydroxyphenacyl. 3. Therapeutic composition having an anti-inflammatory activity, comprising, as active ingredient, a compound according to claim 1 together with a pharmaceutically acceptable carrier, in unit dosage form, each unit dose containing 0.010-0.300 g active ingredient.
Claim 8
Dependent Claim
38 words
Therapeutic composition having an inhibiting activity on blood platelet aggregation, comprising, as active ingredient, a compound according to claim 1 together with a pharmaceutically acceptable carrier, in unit dosage form, each unit dose containing 0.010-0.300 g active ingredient.
Claim 9
Dependent Claim
35 words
Therapeutic composition having an anti-arrhythmic activity, comprising, as active ingredient, a compound as claimed in claim 2, together with a pharmaceutically acceptable carrier, in unit dosage form, each unit dose containing 0.010-0.300 g active ingredient.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-02-20 | 1981-08-22 | 1982-02-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-02-20 | 1985-08-22 | 1986-02-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-02-20 | 1989-08-22 | 1990-02-21 | $7700.00 | Window Closed / Lapsed |